Skip to Main Content

Mark down another failure in the battle against Alzheimer’s disease.

Roche (RHHBY) announced Wednesday morning that it is stopping two clinical trials of a drug it is developing to try to prevent the worsening of Alzheimer’s by targeting protein fragments known as beta-amyloid, which scientists have long believed are a key cause of the brain-destroying disorder. It adds to a heap of failures that includes efforts by just about every large drug company. No medicine has ever been shown to significantly slow Alzheimer’s, and the field has had no successes at all in more than a decade.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • There are differences between the above mentioned antibodies that target different subclasses of amyloid protein. Drug discovery is filled with stories where subtle differences in molecules give remarkable differences in outcome. Agree with the other comment that there is likely a significant immune component to Alzheimer’s- whether triggered by infectious disease, abberant signalling or something else.

Comments are closed.